SITC: Cellectis’ off-the-shelf CAR-T for pancreatic cancer and mesothelioma shows activity in micenews2021-11-12T15:34:40+00:00November 12th, 2021|FierceBiotech|
UPDATED: At the eleventh hour, Woodcock shunned by Biden as Califf becomes FDA commish nomineenews2021-11-12T15:34:14+00:00November 12th, 2021|FierceBiotech|
Gerngross biotech Ankyra Therapeutics nabs $45M series B to jump into the clinic, hires new CMOnews2021-11-12T13:28:14+00:00November 12th, 2021|FierceBiotech|
AstraZeneca wields ax, scrapping midphase programs from $1B takeover, Heptares pact in latest quarterly cullnews2021-11-12T11:05:53+00:00November 12th, 2021|FierceBiotech|
Adaptimmune’s TCR T-cell therapy clears efficacy bar in rare cancers, teeing up landmark solid tumor filingnews2021-11-12T09:48:08+00:00November 12th, 2021|FierceBiotech|
Using CRISPR to find a new drug target for multiple sclerosis, inflammatory bowel diseasenews2021-11-11T21:53:51+00:00November 11th, 2021|FierceBiotech|
Vaxxinity, hoping to turn bodies into their own drug factories, makes a subdued Wall Street debutnews2021-11-11T13:50:20+00:00November 11th, 2021|FierceBiotech|
Organon keeps pedal to the metal, buying up Forendo in 3rd deal since spinning out of Mercknews2021-11-11T13:28:08+00:00November 11th, 2021|FierceBiotech|
Genentech, Novome team up to study seaweed-controlled oral cell therapies in IBDnews2021-11-11T12:51:14+00:00November 11th, 2021|FierceBiotech|
After snapping up Parexel with Goldman Sachs, EQT doubles down on healthcare with Life Sciences Partners buyoutnews2021-11-10T13:20:08+00:00November 10th, 2021|FierceBiotech|
